CMV-Specific TCR-Transgenic T Cells for Immunotherapy
Open Access
- 15 November 2009
- journal article
- Published by The American Association of Immunologists
- Vol. 183 (10), 6819-6830
- https://doi.org/10.4049/jimmunol.0902233
Abstract
Reactivation of CMV can cause severe disease after allogeneic hemopoietic stem cell transplantation. Adoptive T cell therapy was successfully used for patients who had received transplants from CMV-positive donors. However, patients with transplants from CMV-negative donors are at highest risk, and an adoptive therapy is missing because CMV-specific T cells are not available from such donors. To address this problem, we used retroviral transfer of CMV-specific TCR genes. We generated CMV-specific T cell clones of several HLA restrictions recognizing the endogenously processed Ag pp65. The genes of four TCRs were cloned and transferred to primary T cells from CMV-negative donors. These CMV-TCR-transgenic T cells displayed a broad spectrum of important effector functions (secretion of IFN-γ and IL-2, cytotoxicity, proliferation) in response to endogenously processed pp65 and could be enriched and expanded by strictly Ag-specific stimulation. Expansion of engineered T cells was accompanied by an increase in specific effector functions, indicating that the transferred specificity is stable and fully functional. Hence, we expect these CMV-TCR-transgenic T cells to be effective in controlling acute CMV disease and establishing an antiviral memory.Keywords
This publication has 51 references indexed in Scilit:
- Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3–6/6 HLA matched donorsBone Marrow Transplantation, 2008
- Conditional Immortalization of Human B Cells by CD40 LigationPLOS ONE, 2008
- A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transferProceedings of the National Academy of Sciences of the United States of America, 2008
- Monoclonal T-Cell Receptors: New Reagents for Cancer TherapyMolecular Therapy, 2007
- Predictable αβ T-Cell Receptor Selection toward an HLA-B*3501-Restricted Human Cytomegalovirus EpitopeJournal of Virology, 2007
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- αβ T-Cell Receptor Engineered γδ T Cells Mediate Effective Antileukemic ReactivityCancer Research, 2006
- Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjectsThe Journal of Experimental Medicine, 2005
- Late diversification in the clonal composition of human cytomegalovirus-specific CD8+ T cells following allogeneic hemopoietic stem cell transplantationBlood, 2003
- Two subsets of memory T lymphocytes with distinct homing potentials and effector functionsNature, 1999